Contrast-Enhanced Stereotactic Biopsy (CESB): Patient selection and practical considerations

M B I Lobbes,J Theunissen,A Valentijn-Morsing,Y Vissers,L Bouwman
DOI: https://doi.org/10.1016/j.ejrad.2024.111768
2024-09-28
Abstract:Since its introduction in 2012, contrast-enhanced mammography (CEM) has shown increased clinical relevance as a diagnostic tool in breast imaging. Its diagnostic accuracy is on par with breast MRI, rendering it a viable and potentially cost-effective alternative for breast MRI indications, especially in areas with lower accessibility to MRI. Like MRI, CEM occasionally shows 'CEM-only' lesions, i.e., areas of contrast enhancement without corresponding findings on low-energy images, ultrasound, or digital tomosynthesis. The current workaround usually consists of performing MRI-guided biopsy. However, contrast-enhanced stereotactic biopsy (CESB) offers a new alternative and has become commercially available since 2020. This narrative review will outline patient selection, the procedure, important considerations when performing CESB, and an overview of current literature.
What problem does this paper attempt to address?